Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Monday

Key Points

• Voyager is set to release Q1 2026 results before the market opens on May 11, 2026, with analysts forecasting ($0.54) EPS and $8.171M revenue; the company will host an earnings call on May 15 at 4:00 PM ET.
• In the prior quarter Voyager beat estimates, reporting ($0.46) EPS (vs. est. ($0.54)) and $13.46M in revenue, but analysts still expect roughly -$2 EPS for the current and next fiscal years, underscoring ongoing losses.
• Shares have been volatile—rising about 30% on a Novartis deal and trading near $3.76 (market cap ~$227M)—while the CEO and other insiders have sold stock recently and analysts' average rating is "Moderate Buy" with a mean target of $16.50.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Voyager Therapeutics to post earnings of ($0.54) per share and revenue of $8.1710 million for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.08. The company had revenue of $13.46 million during the quarter, compared to analyst estimates of $10.49 million. Voyager Therapeutics had a negative net margin of 296.53% and a negative return on equity of 51.35%. On average, analysts expect Voyager Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Voyager Therapeutics Price Performance

Shares of Voyager Therapeutics stock opened at $3.76 on Monday. The company has a 50-day moving average of $4.01 and a 200 day moving average of $4.08. The firm has a market cap of $227.18 million, a price-to-earnings ratio of -1.85 and a beta of 1.26. Voyager Therapeutics has a 1 year low of $2.64 and a 1 year high of $5.55.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Truist Financial upgraded shares of Voyager Therapeutics to a "strong-buy" rating in a research note on Wednesday, March 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Voyager Therapeutics in a research note on Wednesday, April 15th. HC Wainwright reiterated a "buy" rating and issued a $25.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, March 17th. Finally, Wall Street Zen upgraded shares of Voyager Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, March 14th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $16.50.

Insiders Place Their Bets

In other news, CEO Alfred Sandrock sold 11,511 shares of Voyager Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total value of $44,547.57. Following the completion of the sale, the chief executive officer directly owned 472,549 shares in the company, valued at $1,828,764.63. The trade was a 2.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 61,294 shares of company stock worth $233,241. 4.53% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Voyager Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC boosted its holdings in shares of Voyager Therapeutics by 2.5% in the fourth quarter. Barclays PLC now owns 162,112 shares of the company's stock worth $637,000 after buying an additional 4,003 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Voyager Therapeutics by 1.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 303,133 shares of the company's stock worth $1,191,000 after buying an additional 5,560 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Voyager Therapeutics by 5.1% in the second quarter. American Century Companies Inc. now owns 138,269 shares of the company's stock worth $430,000 after buying an additional 6,748 shares during the last quarter. Jain Global LLC boosted its holdings in shares of Voyager Therapeutics by 44.1% in the third quarter. Jain Global LLC now owns 28,104 shares of the company's stock worth $131,000 after buying an additional 8,600 shares during the last quarter. Finally, Wexford Capital LP purchased a new position in shares of Voyager Therapeutics in the third quarter worth approximately $42,000. Hedge funds and other institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company's core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm's pipeline includes several AAV-based candidates in preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.